Regulus Therapeutics (RGLS)
(Delayed Data from NSDQ)
$2.08 USD
-0.01 (-0.48%)
Updated May 14, 2024 04:00 PM ET
After-Market: $2.07 -0.01 (-0.48%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Regulus Therapeutics Inc. [RGLS]
Reports for Purchase
Showing records 21 - 40 ( 270 total )
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Preclinical Amyotrophic Lateral Sclerosis Studies Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2021 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Phase 2 Alport Syndrome Trial Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Positive Outcome from Pre-IND Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Pre-IND Meeting for RGLS8429 Complete, IND & Ph1 Initiation Planned for Q2:22
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Competitive Drug Candidate Experiences Regulatory Setback; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q3: The Road to Redemption with RGLS8429, IND Acceptance in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Shift in Focus to RGLS8429 Offers Opportunity for Redemption of ADPKD Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q2: Bulked Up Balance Sheet; Focus Remains on Clinical Hold Resolution
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
2Q21 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
PKDCON Data Support Proof-of-Mechanism; Clinical Hold Resolution in H2:21
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Promising RGLS4326 Phase 1b Data; 1Q21 Results; Raising PT to $2
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Q1 Financials; Full ADPKP Cohort 1 Phase 1b Data at PKD Connect in June
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Regulus Therapeutics Inc.
Industry: Medical - Drugs
Topline ADPKD Data Enough to Address Clinical Hold; Selloff Unwarranted
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L